{
    "Trade/Device Name(s)": [
        "CR3 Keyless Split Sample Cup Morphine-Oxazepam"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K140089",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130665"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG",
        "JXM"
    ],
    "Summary Letter Date": "April 8, 2014",
    "Summary Letter Received Date": "January 14, 2014",
    "Submission Date": "January 6, 2014",
    "Regulation Number(s)": [
        "21 CFR 862.3650",
        "21 CFR 862.3170"
    ],
    "Regulation Name(s)": [
        "Opiate test system",
        "Benzodiazepine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Morphine",
        "Oxazepam"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunochromatographic assay",
        "Competitive binding immunoassay"
    ],
    "Methodologies": [
        "Immunochromatography",
        "Antigen-antibody interaction"
    ],
    "Submission Type(s)": [
        "Specimen collection device",
        "Rapid test",
        "Cup"
    ],
    "Document Summary": "FDA 510(k) summary for CR3 Keyless Split Sample Cup Morphine-Oxazepam, a rapid lateral flow immunoassay device for qualitative detection of morphine and oxazepam in human urine.",
    "Indications for Use Summary": "For rapid, qualitative detection of morphine (opiate class) and oxazepam (benzodiazepine class) in human urine at specified cutoff concentrations; intended for over-the-counter and prescription in vitro diagnostic use.",
    "fda_folder": "Toxicology"
}